Athernal Bio is a biotechnology company focused on developing targeted immunotherapies for high-risk clonal haematopoiesis (CH), a prevalent precursor condition to blood cancers such as acute myeloid leukaemia. The company aims to shift oncology treatment from reactive to proactive by preventing cancer development in high-risk patient populations, including those with inherited blood disorders, cancer survivors, and the elderly. Athernal Bio's initial program targets aggressive forms of CH, with the goal of providing early intervention to stop cancer before it starts.